Cost-effectiveness analysis of dabigatran and anticoagulation monitoring strategies of vitamin K antagonist

Table 6 Basic results. Disaggregated costs (€) of the options compared

Years since initiation	PSM			PCpc			Hpc			Hvp			Dabi
Years since initiation	Total	AC	Compl	Total	AC	Compl	Total	AC	Compl	Total	AC	Compl	Total	AC	Compl
Spanish National Health Service Perspective
1	1066	659	407	820	259	562	967	409	558	884	324	560	1454	1058	396
5	3692	1373	2319	3846	644	3202	4296	1124	3173	4148	969	3179	5757	3631	2125
10	6217	1747	4470	6707	800	5907	7269	1415	5854	7096	1231	5865	9026	4981	4045
Lifetime	9118	1938	7179	9668	858	8810	10,266	1521	8745	10,084	1327	8756	12,198	5672	6526
Societal perspective
1	1228	826	402	1081	526	555	1640	1100	540	1557	1015	542	1454	1058	396
5	4059	1755	2305	4648	1501	3147	6367	3339	3029	6221	3184	3037	5757	3631	2125
10	6691	2241	4450	7706	1898	5808	9846	4250	5596	9675	4067	5609	9026	4981	4045
Lifetime	9653	2491	7162	10,728	2043	8685	12,999	4583	8416	12,821	4389	8432	12,198	5672	6526

AC Anticoagulation including INR monitoring plus drug cost; PSM Patient self-management; PCpc Primary care with portable coagulometer; Hpc Hospital care with portable coagulometer; Hvp Hospital care with venipuncture; Dabi Dabigatran; Compl complications